Q1 EPS Forecast for United Therapeutics Lifted by Analyst

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Investment analysts at Leerink Partnrs lifted their Q1 2025 EPS estimates for shares of United Therapeutics in a report released on Friday, April 25th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of $6.48 for the quarter, up from their previous estimate of $6.32. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q2 2025 earnings at $7.20 EPS, Q3 2025 earnings at $8.08 EPS and Q4 2025 earnings at $7.82 EPS.

Several other brokerages also recently commented on UTHR. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a report on Monday, April 21st. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday. Finally, UBS Group increased their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $390.17.

United Therapeutics Stock Down 1.7 %

UTHR stock opened at $291.38 on Monday. The business's fifty day moving average is $308.67 and its 200-day moving average is $346.42. The company has a market cap of $13.09 billion, a P/E ratio of 12.80, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. United Therapeutics has a twelve month low of $233.31 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the prior year, the business posted $4.36 EPS.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Wealthfront Advisers LLC grew its holdings in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the period. Norges Bank bought a new position in United Therapeutics during the fourth quarter worth about $151,764,000. FMR LLC grew its holdings in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after purchasing an additional 393,777 shares during the period. Vaughan Nelson Investment Management L.P. bought a new position in United Therapeutics during the first quarter worth about $101,354,000. Finally, GAMMA Investing LLC grew its holdings in United Therapeutics by 29,415.2% during the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock worth $68,422,000 after purchasing an additional 221,202 shares during the period. Institutional investors own 94.08% of the company's stock.

Insider Activity

In other news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $896,950.62. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,500 shares of company stock worth $24,472,050 in the last quarter. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.